Gratulation zum Kauf von IMMUNE Response - 500 Beiträge pro Seite

[krit]

Allen Brokern meinen Glückwunsch , die meinen Tip zum Kauf von IMMUNE RESPONSE ernst genommen haben!!
Der Wert hat Stärke bewiesen.
Trotzdem rate ich zum setzen einer "stopp loss"-marke bei 2.30 EU!!!!
Sollte der Wert unter 2,00 EU fallen(was ich nicht glaube), kann man günstig nachkaufen.
viel Erfolg wünscht Euch "Krit" !

[Dennie]

Hallo Krit wann und wie hoch war das all Time hoch an der Nasdag? Wo kann man den Handel an der Nasdag Verfolgen?
Danke. Habe mir am 17.04 welche gekauft.

[BII-Aktionär]

Gehe unter Nasdaq.com
IMNR eingeben und dann auf Chart
Das Alltime-Hoch war 1993 bei über 26 Dollar!
Habe Immune auch nach 1 1/2 Jahren Beobachtungszeit endlich am 14.04.01 zu 1.88 Dollar gekauft. Leider nur für 5000 Euro. Aber ich kaufe bei günstigen Kursen (unter 2.30 dollar) nach.

war immer skeptisch was das medikament Remune anging aber jetzt bin ich vom erfolg überzeugt. meine Schätzung: Immune in 2 Jahren über 6 Dollar!

[RCZ]

@ Dennie

für den langfristigen Chart empfiehlt sich ein Blick auf www.bigcharts.com
bei dem Zeitraum all Data anklicken
bei gelegenheit werde ich meinen Thread mit den letzten Meldungen die dort nicht aufgenommen wurden updaten.
Realtimekurse und News bekommst du auf www.freerealtime.com oder www.nasdaq.com
Kürzel für Immune = IMNR

[BII-Aktionär]

Sieht ja gar nicht mehr so übel aus: 4.9$.

wichtig ist, dass wir die 5-dollar-marke wieder zurückerobern..

[BII-Aktionär]

so, 5.05$. und das ist gut so... :-))

Langsam wieder Tritt fassen. nur nichts überstürzen...

Hauptsache über 5 dollar!!!

[BII-Aktionär]

weiss nicht so recht, was ich davon halten soll:

Schlusskurs ist zwar 5.05$ aber nachbörslich wurden grosse Pakete zu 5 dollar gehandelt...

[poorguy]

hey ich hoffe fuer all euch, das ihr alle rechtzeitig raus seid !


poor

[againstfotsch]

könnt ihr mir weiterhelfen?
was ist für den massiven kursrückgang verantwortlich?

thanx

[BII-Aktionär]

06/04/2001
BIOWORLD Today
Copyright 2001 Gale Group Inc. All rights reserved. COPYRIGHT 2001
American Health Consultants, Inc.

After gaining momentum in April with positive data for its HIV drug
Remune, The Immune Response Corp. took a hit Friday, when the company`s
shares lost 55.5 percent on news that a Phase II study in Spain failed
to meet its primary endpoint.

IRC`s stock (NASDAQ:IMNR) closed Friday at $2.18, down $2.72.


"This jeopardizes not only the development of Remune, but the
short-term future of the company," said Alan Auerbach, an analyst with
San Francisco-based Wells Fargo Van Kasper. "I wouldn`t be surprised to
see Pfizer pull out of the deal before the end of the year."

IRC is developing Remune with Agouron Pharmaceuticals Inc., of La
Jolla, Calif., a subsidiary of New York-based Pfizer Inc. "They`re
conducting Phase III studies with Remune that are almost identical in
design [to the failed Phase II study]," Auerbach said.

An independent data safety monitoring board evaluated results from
IRC`s Phase II trial of Remune (HIV-1 Immunogen), and found no
significant difference between the treated group and the control group.
Last year, IRC said preliminary results from the trial were promising.
(See BioWorld Today, June 22, 2000.)

The primary endpoint was time to increase to 5,000 copies/ml of viral
load (the amount of HIV detected in the blood) or a 50 percent decrease
in CD4+ T cells/ml or a decrease to less than 250 CD4+ T cells/ml while
on antiretroviral therapy.

But a subgroup of patients who were more immunocompetent seems to
have shown a decrease in viral load, the board said, calling for more
study. Eduardo Fernandez-Cruz, principal investigator in the study,
said those patients represent the key to making Remune work.

"If you are targeting the immune system of the patient, it`s going to
be important to evaluate a priori whether the immune system is
competent or intact, capable of responding to this type of therapy," he
said. "We started the trial in 1997, and the protocol was written in
1996. At the time, there was no knowledge of what markers would
establish ability to respond. Now, we know."

Other company officials were not available, but Fernandez-Cruz spoke
from a hotel in New York, where they met with the safety board. He said
markers will be used to select patients for a Phase III trial to get
under way "in the next six months."

[BII-Aktionär]

fortsetzung:

He told BioWorld Today "you will never be able to reach a primary
endpoint in unselected populations. But, if we understand the concept
behind the result we have shown, and understand the objective in the
trial, no one in the world would say this has not been successful."

The study was conducted at 13 centers, and was a multicenter,
double-blind, placebo-controlled, randomized trial of 243 antiviral-
naive patients with chronic HIV infection with CD4+ T cells between
300-700 cells/ml. Viral load at entry ranged from less than 10,000
copies/ml to greater than 100,000 copies/ml. Results will be presented
later this month at the Sixth European Conference on Experimental AIDS
Research in Edinburgh, Scotland.

Remune has had a rocky history. In April, IRC`s stock jumped 58
percent, closing at $2.58, on news of data showing that patients
treated with Remune showed a reduction in viral load regardless of
concomitant antiretroviral drug therapy. (See BioWorld Today, April 24,
2001.)

Auerbach, who downgraded IRC`s stock to "underperform," said the firm
has neglected its pipeline. "It`s extensive, but they have just not
executed on development," he told BioWorld Today. "This could be one of
three drugs in Phase III testing."

IRC has IR501, a T-cell receptor peptide vaccine for rheumatoid
arthritis, which has completed two Phase II trials, and IR502, a
similar drug for psoriasis, also in development.

"There`s a million HIV-infected individuals in the U.S., and 2.5
million with rheumatoid arthritis," Auerbach said. "And how about
psoriasis? It`s even higher."

Fernandez-Cruz, however, works only in the HIV program - and he`s
determined to prove Remune`s worth, in selected groups of patients and
potentially larger segments.

"Our studies have been consistent in showing patients that,
conceptually, have competent immune systems will respond, regardless of
viral load," he said. Others won`t respond, no matter what, he added.

"The confusion [about results from the Phase II study] is in the
minds even of the investigators and the evaluators, not in the data,"
he said. "It`s there. It`s clear."

He recalled a conversation with vaccine pioneer Jonas Salk, who told
him "there will be the ones who have the vision, understand the concept
and are able to interpret what they see," but many will not.

"This is not an easy thing to do," Fernandez-Cruz said. "But we`ve
come to a turning point, and from now on, we`ll be in better shape.
This is something that comes step by step. It`s going to take some time."